Physician profile
Samir N Khleif
NPI 1750452892
$337,306.60
in general payments reported to CMS, 2019-2025
12 companies · $62K in 2025
The $62K reported for 2025 was more than what 96% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $21K · 2021: $23K · 2022: $11K · 2023: $66K · 2024: $141K · 2025: $62K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $270K · Food and Beverage: $272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $269,680.00 |
| Food and Beverage | $271.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stemline Therapeutics INC. | $267,625.00 | 2023-2025 | Elzonris |
| Incyte Corporation | $24,907.50 | 2019-2022 | |
| Coherus Oncology, INC. | $15,000.00 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $10,640.89 | 2019-2021 | |
| Emd Serono, INC. | $6,111.39 | 2019 | |
| Astrazeneca Uk Limited | $4,930.85 | 2022-2023 | |
| Gilead Sciences, INC. | $3,400.00 | 2021 | |
| Glaxosmithkline, LLC. | $2,500.00 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $2,055.00 | 2023 | |
| Abbvie INC. | $135.97 | 2024 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samir Khleif listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.